RxDoctor Payments Data

Drew Jones, MD

Dermatology · Greensboro, NCNPI 1902875297

Payments from drug & device makers

$1,787in general payments, 2019–2025

Across 81 payments — averaging $22.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$273
  • Irras USA, Inc.$180
  • Pfizer$162
  • Regeneron Healthcare Solutions, Inc.$161
  • Sun Pharmaceutical Industries Inc.$143
  • UCB, Inc.$120
  • plus $748 from 19 others

What the payments were for

  • Speaking & faculty fees$18010%
  • Food & beverage$1,60790%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,787 in reported general payments places this provider in the 40th percentile of 475 dermatology providers in North Carolina.

See all dermatology providers in North Carolina

Medicare billing

Part B allowed, 2024
$227,678
Medicare patients
708
Services billed
3,781

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OtezlaApremilast29$138,977
Fluorouracil87$6,729
Triamcinolone Acetonide370$5,349
Fluocinonide129$5,241
Metronidazole119$4,783
Acitretin18$4,360
Betamethasone Dipropionate63$3,480
Clobetasol Propionate119$3,246
Ketoconazole116$1,618
Hydrocortisone214$1,457
Mometasone Furoate75$1,204
Desoximetasone32$1,164
Doxycycline Hyclate82$1,127
Azelaic Acid12$1,016
Ampicillin Trihydrate31$969

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$113$138,97729 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 475 dermatology providers in North Carolina.

Other dermatology in Greensboro

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →